Company intelligence / Profile preview

D'tallas

Saint Petersburg, Northwestern Federal District, Russiafacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Tallas Biotech is a pre-clinical biotech company using AI-driven platforms to discover synthetic RNAi therapeutics targeting inflammation and pain. The company leverages advanced computational methods to design stable, effective small interfering RNAs with improved delivery characteristics. No clinical results have been reported yet.

Therapeutic areas: ImmunologyNeurology
Modalities: Small interfering RNASynthetic oligonucleotide
Industry: Biotech

Partnerships

Participates in industry events alongside companies like ProteinQure and others in the RNAi field.

Beyond the preview

Go deeper on D'tallas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D'tallas.

Explore the full profile